Melanie De Almeida
Former journalist intern. Melanie has studied in Germany and Denmark and did an internship at Novo Nordisk, where she had a glimpse to the workings of pharma. She is now a Ph.D. student at the IMP in Vienna.
Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy
New Immuno-oncology Biotech Gets a €20M Series A Funding Boost
Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?
Video Interview: Meet the Inventor of the Surgical Super-glue
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
This Dutch Biotech Could Boost Gene Editing of Primary Cells
BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy
Novartis Negotiates its Way into the US Migraine Market
New Research could Save Patients from Graft-Versus-Host Disease
The World’s Most Expensive Drugs have European Owners
